Anti-N-methyl-D-Aspartate Receptor (NMDAR), Serum

CPT: 86255
Print Share

Expected Turnaround Time

3 - 5 days


Related Documents


Specimen Requirements


Specimen

Serum


Volume

2 mL


Minimum Volume

1 mL (Note: This volume does not allow for repeat testing.)


Container

Serum from a gel-barrier tube, serum from a red-top tube, gel-barrier tube, serum transfer tube


Storage Instructions

Room temperature


Stability Requirements

TemperaturePeriod
Room temperature14 days
Refrigerated14 days
Frozen14 days
Freeze/thaw cyclesStable x3

Causes for Rejection

CSF or plasma; contaminated, hemolyzed, or severely lipemic specimens


Test Details


Use

NMDAR1 is a glutamate receptor and ion channel found in neurons. This receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions. Antibodies against NMDAR1 generate both neurologic and psychiatric symptoms. Common symptoms include personality change, psychosis, abnormal movements, seizures and autonomic dysfunction. Anti-NMDA receptor IgG antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis.


Limitations

Results should not be used as a diagnostic procedure without confirmation by another medically established diagnostic product or procedure.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


Methodology

Immunofluorescence (IFA)


Additional Information

Anti-NMDAR1 encephalitis represents one of the most frequent causes of autoimmune encephalitis. This type of encephalitis may also be associated with post-COVID-19 related neurological symptoms.


References

Lynch DR, Rattelle A, Dong YN, Hoslin K, Gleichman AJ, Panzer JA. Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms. Adv Pharmacol. 2018;82:235-260.29413523
Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev. 2014 Sep;36(8):645-652.24211006
Scheer S, John RM. Anti-N-Methyl-D-Aspartate Receptor Encephalitis in children and Adolescents. J Pediatr Health Care. 2016 Jul-Aug:30(4):347-358.26507948
Venkatesan A, Adatia K. Anti-NMDA-Receptor Encephalitis: From Bench to Clinic. ASC Chem Neurosci. 2017 Dec 20;8(12):2586-2595.29077387
Zandifar A, Badrfam R. COVID-19 and anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis: Are we facing an increase in the prevalence of autoimmune encephalitis? J Med Virol. 2021 Apr;93(4):1913-1914.33336825

LOINC® Map

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf